Compare Main Street Capital Corporation (MAIN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Main Street Capital Corporation trades at $53.66 (market cap $5.00B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.94% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MAIN | SYRE | |
|---|---|---|
Market Cap | $5.00B | $7.35B |
Volume | 454,409 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $64.60 | $108.92 |
52-Week Low | $49.63 | $22.18 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $7.48B | $6.35B |
Dividend Yield | 5.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $53.77, up slightly by 0.2% on the day, amid a bearish technical outlook with selling pressure on moving averages. The company reported a net income of $493.40M on revenue of $591.85M for 2025, with a high net margin of 80.77%. Recent earnings show a mix of beats and misses, while analysts maintain a consensus price target of $58.00 with a Hold-heavy rating distribution.
The stock presents a stable dividend profile with consistent payouts, but faces headwinds from softening revenue projections into 2026 and negative operating cash flow. Investment appeal hinges on NAV growth and dividend sustainability, though elevated Treasury yields and premium valuation pose risks to near-term performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
